Figure 6.

Synergistic anti-leukemic effects of atuveciclib and venetoclax. (A) Separate and combined incubations of atuveciclib and venetoclax in dose-response format; combined incubation exemplified by atuveciclib dose-response treatment at 0.3 µM venetoclax concentration; y axis: relative viability (5 of vehicle control) of T-cell prolymphocytic leukemia cell sample 25 incubated for 48 h with respective compound determined by CellTiterGlo^™ detection methods; half-maximal inhibition (IC50) was determined using Combenefit software and is depicted below each graph; x axis: respective compound concentration in µM. (B) Left: two-dimensional representations upon highest single agent (HSA) analysis using Combenefit software (coloration: red/orange pointed antagonism, green additive effects, and blue indicated synergy); right: relative viabilities (y axis) after incubation with different concentrations of atuveciclib (x axis; 20 nM to 3 µM) and venetoclax (z axis; 2 nM to 1 µM). Similar combinatorial effects were obtained with three different donors.